Oragenics Inc. (OGEN) shares soared 29.86% in after-hours on Monday, January 03, 2022, and closed the daily trading at $0.61. Even in the regular trading session on Monday, OGEN’s stock gained 6.01%. OGEN shares have fallen 9.06% over the last 12 months, and they have moved down 0.04% in the past week. Over the past three months, the stock has lost 23.33%, while over the past six months, it has declined 29.01%.
Let’s discuss its recent news and developments.
OGEN collaboration extended with NRC Canada
On December 20, 2021, Oragenics, Inc. (OGEN) extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
Oragenics will use NRC cell expression technologies that can generate cell lines in a short time for high-yield production of spike protein antigens for existing and emerging variants of concern. The NRC technologies will accelerate the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.
OGEN participation in a recent event
Oragenics, Inc. (OGEN) recently participated in a fireside chat at Alliance Global Partners (AGP) Virtual Series which was held on Tuesday, December 14, 2021. The company was presented by Frederick W. Telling, Ph.D., Executive Chairman during the event.
Publication of OGEN lantibiotics Study
On December 08, 2021, Oragenics, Inc. (OGEN) published a study entitled “Lipid II Binding and Transmembrane Properties of Various Antimicrobial Lanthipeptides.” The study was published in the Journal of Chemical Theory and Computation.
Due to the significant rise in antibiotic-resistant infections in recent years, there is utmost need to develop new antimicrobials. Organics lantibiotics are promising candidates to fight antibiotic-resistant bacteria due to their unique and dual mode of action, including interference with cell wall synthesis by binding to Lipid II and creation of unique pores in bacterial membranes.
Positive study results of OGEN Covid vaccine
On December 01, 2021, Oragenics, Inc. (OGEN) announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge.
The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays. However, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads.
Upcoming annual meeting of shareholders
On November 22, 2021, Oragenics, Inc. (OGEN) ’s Annual Meeting of Shareholders was adjourned, due to lack of the required quorum, without any business being conducted.
The Annual Meeting was adjourned to 4:00 p.m. (Eastern Time) on Tuesday, January 25, 2022, at the offices of Shumaker, Loop, & Kendrick, Bank of America Plaza, 101 E Kennedy Blvd., Suite 2800, Tampa, FL 33602.
Well, as of this writing, we had no recent news or development which could justify its exceptional performance on the first trading day of the new year. We hope that it will continue its positive momentum in the coming trading sessions.